Historique de carrière de Ira Wallis
Anciens postes connus de Ira Wallis
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
Tercica, Inc.
 Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Conseiller Juridique Général | - | 03/02/2014 |
| DYNAVAX TECHNOLOGIES CORPORATION | Conseiller Juridique Général | 01/05/2001 | 01/01/2003 |
| CERUS CORPORATION | Directeur/Membre du Conseil | 01/07/1996 | 01/04/2001 |
| Conseiller Juridique Général | 01/07/1996 | 01/04/2001 | |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Conseiller Juridique Général | 01/01/1990 | 01/01/1996 |
| Sandoz Pharmaceuticals Corp. | Conseiller Juridique Général | 01/01/1987 | 01/01/1989 |
Formation de Ira Wallis
| American International College | Undergraduate Degree |
| State University of New York at Buffalo | Doctorate Degree |
Statistiques
Internationale
| Etats-Unis | 8 |
Opérationnelle
| General Counsel | 5 |
| Director/Board Member | 1 |
| Undergraduate Degree | 1 |
Sectorielle
| Health Technology | 5 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| DYNAVAX TECHNOLOGIES CORPORATION | Health Technology |
| CERUS CORPORATION | Health Technology |
| Entreprise privées | 3 |
|---|---|
Tercica, Inc.
Tercica, Inc. Pharmaceuticals: MajorHealth Technology The Company's principal activity as a biopharmaceutical company is focused on the development and commercialization of products to improve endocrine health. Its first product, IncrelexTM (mecasermin {rDNA origin} injection), or recombinant human insulin-like growth factor-1 (rhIGF-1), is approved by the FDA for the treatment of severe Primary IGFD. The Company licensed the rights to develop, manufacture and commercialize Increlex from Genentech Inc. | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
| Sandoz Pharmaceuticals Corp. |
- Bourse
- Insiders
- Ira Wallis
- Expérience
